Lupin Recalls 51,000 Bottles of Generic Antibiotics in the U.S. Due to Temporary Health Issues
In a significant development, leading pharmaceutical firm Lupin has initiated a recall of over 51,000 bottles of its generic antibiotic medication, Cefdinir for Oral Suspension (250 mg/5 mL), from the U.S. market. This recall, highlighted by the U.S. Food and Drug Administration (USFDA) in its latest Enforcement Report, stems from a “defective container: lack of seal integrity,” which potentially impacts the medication's safety and efficacy. Cefdinir is a widely prescribed antibiotic used to treat a variety of bacterial infections, making this recall particularly noteworthy for both healthcare providers and patients relying on this medication. The recall affects 51,006 bottles, all manufactured at Lupin’s facility in Mandideep, India, and distributed in the U.S. by its Baltimore-based subsidiary, Lupin Pharmaceuticals, Inc. The recall, classified as a Class II recall by the USFDA, indicates that the product in question might lead to temporary or medically reversible adverse ...
